Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Heinz Ludwig, MD, professor of internal medicine and hematology-oncology at Wilhelminen Cancer Research Institute, Wilhelminenspital in Vienna, Austria, discusses the incidence of increased infections in patients with multiple myeloma.
Patients with multiple myeloma are at increased risk to develop infections due to its significant impact on one's immune system. In a study, Ludwig et al discovered that about 56% of patients had 1 or more infectious episodes prior to their diagnosis due to the innate immune system.
According to Ludwig, a majority of the viral infections which occur in patients with multiple myeloma are in the upper respiratory tract and primarily consist of viral infections. However, infections of the bloodstream, urinary tract infections and those caused by bacteria are also common.
Transcription:
0:08 | We did a study, which showed that myeloma patients, about 56% of patients, had already 1 or more infectious episodes in the year before the diagnosis was established. Patients are at increased risk and the increased risk is already affecting about half of patients before any treatment has been initiated. The disease itself is immunosuppressive, it has a significant impact on what we call the innate immune system.
0:54 | Then when patients are treated, they are the complications of inside effects of therapy. Usually when they are treated, there's more disease which motivates people to start therapy. In addition, there is a gender difference. Male myeloma patients are at a 20% higher risk of infections compared to females. As you know, male patients have slightly poorer survival expectancy compared to female patients.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
2 Commerce Drive
Cranbury, NJ 08512